Marker Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Marker Therapeutics (MRKR).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

1S.Buy

3Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$12Upside to Avg. PT+1198.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 8, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Initiate	Buy	$10
Apr 1, 2025	WBB Securities	Steve Brozak	Maintained	Strong Buy	$13
Mar 5, 2025	Canaccord Genuity	John Newman	Initiate	Buy	$8
Oct 21, 2024	Ladenburg Thalmann	Aydin Huseynov	PT Raise	Buy	$11→$19
Apr 30, 2024	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$11

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

WBB Securities analyst Steve Brozak reiterates Marker Therapeutics (NASDAQ:MRKR) with a Strong Buy and maintains $12.5 price target.

Benzinga Newsdesk

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

PRO
Canaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

Canaccord Genuity analyst John Newman initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy t

Vandana Singh

Marker Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Marker Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

PRO
WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Canaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Ladenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

People Also Watch

People Also Watch

Marker Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Marker Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

PROWBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROCanaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

PROLadenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

PRO
WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target

PRO
Canaccord Genuity Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Ladenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11